Pterostilbene

Mechanism of action

Proposed mechanisms (mainly from in vitro/animal data): (1) Activation of endogenous antioxidant responses (e.g. via Nrf2) with increased detoxifying/antioxidant enzymes; (2) Modulation of AMPK and potential cross-talk with SIRT1, with effects on mitochondrial biogenesis and energy metabolism; (3) Interaction with PPARs (especially PPAR-α/γ in some models), influencing fatty acid oxidation and insulin sensitivity; (4) Inhibition of pro-inflammatory signaling (e.g. NF-κB) and reduction of inflammatory mediators; (5) Effects on the endothelium and vascular function in experimental models. In humans, the mechanisms are inferred indirectly from biomarkers and have not been fully confirmed.

Supported benefits

• Possible improvement in some metabolic markers (e.g. fasting glucose or insulin sensitivity) in specific populations and experimental contexts (limited)
• Possible reduction in some inflammatory/oxidative markers in small or short-duration studies (emerging)
• Effects on the lipid profile: mixed results; in some studies, an increase in LDL cholesterol was observed, a relevant factor for evaluating the risk/benefit balance (moderate)
• Support for endothelial/vascular function: evidence is predominantly preclinical, with little indirect clinical data (emerging)
• Neuroprotection and cognitive support: strong preclinical rationale, but robust clinical confirmation is lacking (emerging)

Safety & side effects

• Gastrointestinal disturbances (e.g. nausea, dyspepsia, diarrhea) reported occasionally
• Headache or nonspecific sensations (nonspecific reports and not always attributable)
• Possible increase in LDL cholesterol in some studies: a clinically relevant adverse event for individuals at cardiovascular risk

FAQ

Is it “better” than resveratrol?

It is more lipophilic and is often described as having more favorable pharmacokinetics, but this does not automatically imply greater clinical efficacy. Evidence in humans for both is limited and depends on the endpoint considered.

Is there solid evidence for longevity in humans?

No. There are biological rationales and preclinical data, but long-term clinical studies with longevity endpoints or reduction in major clinical events are lacking.

Can it affect cholesterol?

Yes: some studies have reported an increase in LDL cholesterol. This is an important safety consideration, especially for those at cardiovascular risk.

How long has it been studied in humans?

Mainly in short- to medium-term studies (weeks). Data on prolonged use are insufficient for robust conclusions.

Is it present in foods in significant amounts?

It is present in some plant sources (e.g. blueberries) but generally in low amounts compared with the doses used in supplement studies.